PreferredStockChannel
Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Wed, July 17, 6:31 PM
| This Slide: #3 of 462 |
Slide #3. Sunesis Pharmaceuticals, Inc. — Preferred Stock Offering
Company:
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Date announced:
7/10/2019
Preferred Stock Offering Details:
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.
Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new therapeutics for the treatment of cancer. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Co.'s primary program is vecabrutinib, a non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.
Open the SNSS Page at Preferred Stock Channel »
|
|||||||||||||||||||||
|
|
Open the SNSS Page at Preferred Stock Channel (in a new window) »
|
|
Avg. Broker Rec.
 
|
Buy (3.00 out of 4) 39th percentile
(ranked lower than approx. 61% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
